<DOC>
	<DOCNO>NCT02173977</DOCNO>
	<brief_summary>The purpose study evaluate appropriate control ovarian hyperstimulation ( COH ) protocol good prognosis patient undergoing IVF treatment . The stimulation characteristic cycle include ultrashort flare GnRH agonist combine flexible multidose GnRH antagonist compare flexible multidose GnRH antagonist protocol . The investigator hypothesize combine stimulatory effect GnRH agonists immediate suppression GnRH antagonist unique protocol may valuable new COH strategy IVF patient , result improved ART outcome .</brief_summary>
	<brief_title>Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF</brief_title>
	<detailed_description>The ultrashort flare GnRH agonist combine flexible multidose GnRH antagonist protocol COH cycle result significantly high clinical pregnancy rate patient poor embryo quality , repeat IVF failure poor responder . This protocol combine effect microdose flare endogenous follicle stimulate hormone ( FSH ) release benefit immediate luteinizing hormone suppression GnRH antagonist . The basic hypothesis approach also benefit IVF patient good prognosis without compromise ability use gonadotrophin-releasing hormone ( GnRH ) agonist effectively trigger ovulation , completely eliminate threat clinically significant ovarian hyperstimulation syndrome ( OHSS ) . The purpose study compare cycle consist ultrashort flare GnRH agonist combine flexible multidose GnRH antagonist use flexible multidose GnRH antagonist protocol 1 . To compare IVF outcome variable ongoing pregnancy rate .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Up three previous IVF attempt Patients poor response previous COH IVF cycle Abnormal ovarian reserve test i.e . antimullerian hormone ( AMH ) , Antral follicle test Risk factor Diminished Ovarian Reserve</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>GnRH Agonist</keyword>
	<keyword>GnRH Antagonist</keyword>
	<keyword>OHSS</keyword>
</DOC>